Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641056 | 0.88 | PTGS2 (0.61) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8989633 | 0.87 | PTGS2 (0.64) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL8638794 | 0.87 | PTGS2 (0.60) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8639285 | 0.85 | PTGS2 (0.59) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8635868 | 0.85 | PTGS2 (0.58) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8989413 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6013911 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL6268681 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL6341663 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1PDPK1CA1CA2 | |
| SCHEMBL8641301 | 0.82 | PTGS2 (0.62) | PTGS2PTGS1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| US-20060167075-A1 | Modulators of FAAH | IRONWOOD PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167075-A1 | Modulators of FAAH | FAAH, FAAH2, HCRTR2 | PTGS2 107/4885PTGS1 73/4885PDPK1 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.